Page 323 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

12. COMPLEXES DUPLATINE 279

MÉCANISMES DE RÉSISTANCE
DABHOLKAR M. et al., Messenger RNA levels of XPAC and ERCC1 in ovarian cancer
tissue correlate with response to platinum-based chemotherapy, J. Clin. lnvest., 1994,
94, 703-708.
KOROPATNICK J. et al., Metallothionein expression and resistance to cisplatin in a
human germ cell tumor cell line, J. Pharmacol. Exp. Ther., 1995, 275, 1681-1687.
EL-AKAWIZ. et al., Altered glutathione metabolism in oxaliplatin resistant ovarian carci-
noma cells, Cancer Lett., 1996, 105, 5-14.
GHAZAL-ASWAD S. et al., The relationship between tumor glutathione concentration,
glutathione S-transferase isoenzyme expression and response to single agent carbo-
platin in epithelial ovarian cancer patients. Br. J. Cancer, 1996, 74, 468-473.
FINK D. et al., ln vitro and in vivo resistance to cisplatin cells that have lost DNA mismatch
repair, Cancer Res., 1997, 57, 1841-1845.
HISHIKAWA Y. et al., Overexpession of metallothionein correlates with chemoresistance
to cisplatin and prognosis in esophageal cancer, Oncology, 1997, 54, 342-347.
KUROKAWA H. et al., Effect of glutathione depletion on cisplatin resistance in cancer
cells transfected with the y-glutamylcysteine synthetase gene, Jpn J. Cancer Res.,
1997, 88, 108-110.
HOLFORD J. et al., Chemical, biochemical and pharmacological activity of the navel
sterically hindered platinum coordination complex, cis-[amminedichloro(2-methylpy-
ridine)] platinum(II) (AMD473), Anti-CancerDrug Des., 1998, 13, 1-18.
KOJIMA H. et al., Abrogation of mitochondrial cytochrome c release and caspase-3 acti-
vation in acquired multidrug resistance, J. Bio/. Chem., 1998, 273, 16647-16650.
MULLER M. et al., p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage
by anticancer drugs, J. Exp. Med., 1998, 188, 2033-2045.
NAGANE M. et al., Drug resistance of human glioblastoma cells conferred by a tumor-
specific mutant epldermal growth factor receptor through modulation of Bel-XL and
caspase-3-like proteases, Proc. Nat/. Acad. Sei. U. S. A., 1998, 95, 5724-5729.
VAISMAN A. etal., The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and
oxaliplatin resistance : correlation with replicative bypass of platinum-DNA adducts,
Cancer Res., 1998, 58, 3579-3585.
WELTERS M.J.P. et al., Role of glutathlone, glutathione S-transferases and multidrug
resistance-related proteins in cisplatin sensitivity of head and neck cancer cell lines,
Br. J. Cancer, 1998, 77, 556-561.
BASU A., et al., Regulation of caspase activation and cis-diamminedichloroplatinum(ll)-
induced cell death by protein kinase C, Biochemistry, 1999, 38, 4245-4251.
CHAU Q., STEWART D.J., Cisplatin efflux, binding and intracellular pH in the HTB56
human Jung adenocarcinoma cell line and the E-8/0.7 cisplatin-resistant variant, Can-
cer Chemother. Pharmacol., 1999, 44, 193-202.
FERRY K. N. et al., Decreased cisplatin damage-dependent DNA synthesis in cellular
extracts of mismatch repair deficient cells, Biochem. Pharmacol., 1999, 57, 861-867.
HANIGAN M.H. et al., y-Glutamyl transpeptidase accelerates tumor growth and
increases the resistance of tumors to cisplatin in vivo, Carcinogenesis, 1999, 20, 553-
559.